Literature DB >> 8541003

Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.

E Rossi1, C Sani, F Perazzoli, M C Casoli, A Negro, C Dotti.   

Abstract

In order to investigate the possible existence of abnormal calcium metabolism and parathyroid function in primary aldosteronism (PA), we have compared the calcium/parathyroid hormone (PTH) profile of patients with PA with the profile of healthy normotensive subjects and of patients with essential hypertension (EH). Furthermore, we have evaluated the effects of spironolactone and the surgical removal of aldosterone-producing adenomas on the calcium/PTH profile in the PA patients. Four groups of 10 subjects each participated in the study: 1) hypertensive patients with PA, 2) patients with low-renin EH (LREH), 3) patients with normal-renin EH (NREH), 4) normotensive healthy subjects (NS). The four groups were well-matched for age, sex, body mass index, and renal function. The three hypertensive groups were also matched closely for blood pressure values and for duration of hypertension. In all subjects, after 1 week of a controlled intake of Na and K, the following parameters were measured: urine excretion of Na, K, Ca, Mg, and P, plasma levels of K, Mg, inorganic P, total calcium and ionized calcium, and plasma renin activity, aldosterone concentration, and intact PTH. Blood pressure and laboratory parameters were determined again in all the PA patients after 1 month of 100 mg daily spironolactone administration, and in four out of the 10 PA patients 2 months after surgical removal of aldosterone-producing adenomas. All of these subjects had undergone the same controlled intake of Na and K indicated above. Serum intact PTH was higher in PA patients than in the other three groups (P < .01), and serum ionized calcium was significantly higher in normotensive subjects than in the three hypertensive groups (v PA P < .01, v LREH and v NREH P < .05). An increase in serum ionized calcium and a decrease in PTH level were associated with both spironolactone administration (P < .001) and surgical treatment (P < .05). These results suggest the presence of calcium metabolism alterations in both PA and EH patients, but that these alterations are more exaggerated in PA, so that higher PTH levels are needed for maintaining low-normal levels of serum ionized calcium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541003     DOI: 10.1016/0895-7061(95)00182-O

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  38 in total

Review 1.  The DASH trials implicate dysfunction in calcium regulation in the pathogenesis of human hypertension.

Authors:  A G Logan
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism.

Authors:  Malay S Gandhi; Prajwal A Deshmukh; German Kamalov; Tieqiang Zhao; Wenyuan Zhao; Jonathan T Whaley; Jill R Tichy; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2008-09       Impact factor: 3.105

3.  Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones.

Authors:  Omar Bayomy; Sarah Zaheer; Jonathan S Williams; Gary Curhan; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 4.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 5.  Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones.

Authors:  Jawwad Yusuf; M Usman Khan; Yaser Cheema; Syamal K Bhattacharya; Karl T Weber
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

Review 6.  The Endocrine Role of Bone in Cardiometabolic Health.

Authors:  Rosemary DeLuccia; May Cheung; Rohit Ramadoss; Abeer Aljahdali; Deeptha Sukumar
Journal:  Curr Nutr Rep       Date:  2019-09

7.  Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.

Authors:  Krishna Gaddam; Cecilia Corros; Eduardo Pimenta; Mustafa Ahmed; Thomas Denney; Inmaculada Aban; Seidu Inusah; Himanshu Gupta; Steven G Lloyd; Suzanne Oparil; Ahsan Husain; Louis J Dell'Italia; David A Calhoun
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

Review 8.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

9.  Symptomatic hypocalcemia in primary hyperaldosteronism: a case report.

Authors:  Sachin G Pai; K N Shivashankara; V Pandit; S Sheshadri
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.

Authors:  Jenifer M Brown; Jonathan S Williams; James M Luther; Rajesh Garg; Amanda E Garza; Luminita H Pojoga; Daniel T Ruan; Gordon H Williams; Gail K Adler; Anand Vaidya
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.